

*Aut E 2*  
Claim 18 (Amended). An isolated polypeptide having an amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, 8, 10, 14, 16, 55 to 75, 77 to 79, 81 or 83.

*Aut E 3*  
Claim 19 (Amended). An isolated polypeptide according to claim 18, wherein the N-terminal methionine residue of the polypeptide is deleted.

*Aut E 4*  
Claim 20 (Amended). An isolated polypeptide according to claim 18, wherein the secretory amino acid sequence of the polypeptide is deleted.

*Aut E 5*  
Claim 25 (Amended). A vaccine composition comprising a polypeptide having at least 95% identity with a second polypeptide having an amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, 10, 14, 16, 55, 58, 60, 62 to 69, 71 to 75, 77 to 79, 81 or 83, or a combination thereof and a pharmaceutically acceptable carrier, diluent or adjuvant.

Please add the following claims:

*Aut E 6* ✓ Claim 32. (New) An isolated polypeptide having an amino acid sequence of SEQ ID NOs: 2, 10, 55, 58, 64, 65 or 66.

*Aut E 7*  
Claim 33. (New) A vaccine composition comprising a polypeptide having an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 55, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO:

62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO:65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO: 79 .

E4

Claim 34. (New) A vaccine composition according to claim 25 wherein the polypeptide lacks an N-terminal methionine residue.

5

Claim 35. (New) A vaccine composition according to claim 25 wherein the polypeptide lacks a secretory amino acid sequence.

Claim 36. (New) An isolated polypeptide having at least 95 % identity with a second polypeptide comprising an amino acid sequence of any one of SEQ ID NOs.10, 58, 64, 65 and 66.

Claim 37. (New) A vaccine composition comprising a having at least 95% identity with a second polypeptide having an amino acid sequence of any one of SEQ ID NOs, 10, 58, 64, 65 and 66 or a combination thereof and a pharmaceutically acceptable carrier, diluent or adjuvant.

#### REMARKS

Favorable reconsideration of the subject application, in view of the amendments above and comments below, is respectfully requested.